A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Norman Wolmark, MD
NSABP Foundation Inc
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uf Health Davis Cancer Pavilion and Shands Med Plaza
Gainesville, Florida, United States
- University of Iowa
Iowa City, Iowa, United States
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
- Ahn Cancer Institute
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Jun 2022
- Primary completion
- 28 Feb 2026
- Completion
- 28 Feb 2027
- Last update posted
- 4 Nov 2022
- Registered enrollment
- 0
- Registry id
- NCT05178576
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.